The Respiratory Revolution That's Already Happening
From Hutchinson's 1846 Spirometer to Continuous Digital Monitoring: Why 175 Years of Innovation Is Finally Reaching 545 Million Patients
March 3rd, 2026
In 1846, an English surgeon named John Hutchinson invented spirometry with a counterbalanced bell inverted in water and a singular ambition: to detect lung disease before symptoms appeared and predict mortality with precision [1]. He performed spirometry on 2,130 subjects, sailors, paupers, artisans, pugilists, compositors and draymen, and found that reduced vital capacity preceded early death, often from tuberculosis [1]. His revolutionary insight was this: the lungs reveal disease trajectories long before patients feel unwell.
One hundred and seventy-five years later, we're still bringing patients to the clinic for fundamentally the same episodic test. The bell has been replaced with electronic sensors, yet the clinical paradigm remains unchanged: measure once, diagnose reactively, monitor sporadically. Meanwhile, 545 million people worldwide suffer from chronic respiratory diseases [2]. Seventy per cent of COPD cases remain undiagnosed until severe symptoms force clinical presentation [3]. Patients with idiopathic pulmonary fibrosis face a median survival of three to five years from diagnosis because we identify the disease far too late [4].
We've succeeded in placing continuous cardiac monitoring on millions of wrists through consumer wearables. We've made glucose monitoring a routine for diabetic patients. Yet the organ system that defines whether we live or die with every breath has remained largely unmonitored outside the clinical laboratory, until now.
The Historical Foundation and Its Limitations
Hutchinson's spirometer was extraordinary for its era, but even more remarkable was his methodology. He understood that lung function measurements required population-based reference values, standardised techniques, and longitudinal tracking. These principles remain valid today. His work established spirometry as the cornerstone of respiratory diagnostics, a position it has held for nearly two centuries.
The evolution from Hutchinson's water-sealed spirometer to modern electronic devices represents genuine technological progress. In 1947, French physicians Robert Tiffeneau and André Pinelli introduced the forced expiratory volume in one second (FEV₁), revolutionising our ability to detect and quantify airway obstruction. The 1979 Snowbird Conference established international standards for spirometry testing, creating reproducible methodologies that enabled meaningful clinical research and practice guidelines. Portable electronic spirometers emerged in the 1990s, promising to bring lung function testing into primary care settings where early detection could have the greatest impact.
Yet despite these advances, clinical adoption stagnated. Studies consistently show that spirometry is underused by primary care physicians, even for patients with obvious respiratory symptoms and risk factors [5]. When spirometry is performed outside specialist centres, test quality is frequently inadequate, and interpretation is often incorrect. The vision of universal early detection through spirometry has remained frustratingly out of reach.
Why the Traditional Model Failed
The barriers to spirometry adoption are systemic, not technical. Primary care clinics lack trained personnel, face time pressures that make careful spirometry impractical, and struggle with equipment maintenance and quality assurance. Patients must travel to testing facilities, which often requires taking time off work. Results then arrive days later, disconnected from the clinical moment. Reimbursement models also frequently don't support the investment needed for quality spirometry programmes.
But the fundamental limitation runs deeper than logistics: episodic testing cannot capture dynamic disease processes. The iconic Fletcher-Peto curve, published in 1977, shaped respiratory medicine for decades by depicting COPD as a steady decline in FEV₁ from smoking-induced lung damage [6]. This elegant model influenced everything from screening programmes to therapeutic trials. There was only one problem, recent research has demonstrated it's substantially incorrect.
Longitudinal studies tracking thousands of patients over decades reveal that roughly half of the people who develop COPD never follow the predicted rapid-decline trajectory [7]. Instead, they have low lung function in early adulthood that remains relatively stable [7]. Meanwhile, standard spirometry misses disease in the small airways until more than 50% have been affected, meaning we're diagnosing obstruction only after extensive, often irreversible damage has occurred [8].
Add to this the emergence of multiple COPD phenotypes, the controversial asthma-COPD overlap syndrome, and the reality that patients with symptomatic disease and radiographic abnormalities often show normal spirometry. The uncomfortable truth becomes clear: we're using a 175-year-old diagnostic paradigm, based on single-point-in-time forced expiratory manoeuvres, to classify a heterogeneous, dynamically progressive group of diseases. This mismatch explains why pharmaceutical trials fail, why early intervention strategies underperform, and why 70% of COPD remains undiagnosed [3].
The Convergence That Changes Everything
Three enabling factors have converged to make continuous respiratory monitoring finally achievable at the population scale:
Ubiquitous smartphones with clinical-grade sensors and computational power
Artificial intelligence capable of real-time signal processing and interpretation
Regulatory frameworks that have matured to support digital health technologies
Several innovative platforms are now demonstrating that smartphone-based respiratory monitoring can achieve clinical-grade accuracy comparable to laboratory spirometry. Early clinical investigations involving hundreds of patients are showing agreement rates exceeding 95% with traditional spirometry for key diagnostic parameters. More importantly, these platforms enable what episodic testing never could: continuous tracking of respiratory function in patients' daily environments, capturing disease progression in real time, and identifying deterioration before clinical symptoms emerge.
This is not an incremental improvement; it represents a fundamental shift in how we approach respiratory disease. The analogy to wearable cardiac monitors or continuous glucose monitoring is instructive. These technologies succeeded not merely by replicating laboratory tests more conveniently, but by revealing dynamic physiological patterns invisible to episodic measurement. Heart rate variability, nocturnal glucose excursions, and response to physical activity: these insights transformed disease management. Respiratory medicine is poised for the same transformation.
Transforming Therapeutic Development and Clinical Trials
For pharmaceutical executives, the implications are profound. Drug development in respiratory disease has been hampered by trial designs based on outdated disease models and inadequate outcome measures. Consider the challenges:
Current COPD trials enrol heterogeneous populations using FEV₁ thresholds that capture multiple distinct phenotypes, some with predominant small airways disease, others with parenchymal destruction, and still others with reversible components. We then ask whether a single therapeutic approach works across this diverse group, using crude endpoints like exacerbation rates or modest FEV₁ changes that may not reflect clinically meaningful benefit. Only 85% of COPD drugs make it past Phase 3 trials [9].
In idiopathic pulmonary fibrosis trials, we rely on forced vital capacity decline as a surrogate endpoint, despite ongoing controversy about whether FVC changes genuinely predict mortality or quality of life improvements. We're measuring what's convenient to measure, not what matters most to patients.
Continuous respiratory monitoring addresses these fundamental limitations. Imagine clinical trials where:
Patient phenotyping occurs through longitudinal function tracking rather than single measurements, enabling precise stratification before randomisation
Treatment response is assessed through trajectory analysis. Did the therapeutic intervention alter disease progression? Rather than comparing mean values at arbitrary timepoints
Early signals of efficacy or futility emerge within weeks rather than months, enabling adaptive trial designs that accelerate development timelines
Real-world evidence generation begins at market authorisation, with continuous post-marketing surveillance revealing effectiveness across diverse populations and settings
Several pharmaceutical companies are already exploring partnerships with continuous monitoring platforms, recognising that the data infrastructure for next-generation trial design must be built now. The competitive advantage will accrue to organisations that embrace this transition early, reimagining their clinical development programmes around continuous, patient-generated health data rather than episodic clinic-based assessments.
The Technology Platform Opportunity
For technology executives at companies like Google and Apple, respiratory monitoring represents the last major vital sign category yet to be digitally transformed at scale. Consider the market dynamics:
Five hundred and forty-five million people worldwide live with chronic respiratory disease [2]. The global burden of COPD alone exceeds $500 billion annually in direct healthcare costs and productivity losses [10]. Asthma affects more than 300 million people [11]. Interstitial lung diseases, whilst individually rare, collectively represent a substantial unmet clinical need. The total addressable market dwarfs many disease categories that have received more attention from digital health innovators.
Moreover, respiratory monitoring exhibits classic platform characteristics. Initial adoption for diagnostic purposes creates network effects: more users generate richer datasets, enabling better machine learning algorithms that improve diagnostic accuracy and attract more users. The platform then expands from diagnostics into continuous monitoring, from monitoring into therapeutic delivery systems, from therapeutics into predictive analytics for healthcare systems and insurers.
The technical barriers to entry are substantial, which limit competition. Unlike step counting or basic heart rate monitoring, respiratory function assessment requires sophisticated signal processing, clinical-grade accuracy validation, and complex interpretation algorithms. Regulatory pathways demand rigorous clinical evidence. These high barriers protect first movers who execute well.
The market timing is particularly compelling. Ageing populations in developed economies, increasing air pollution in emerging markets, and the long-term respiratory sequelae of COVID-19 are driving respiratory disease prevalence upward [12]. Healthcare systems are actively seeking solutions that shift care from expensive hospital settings into homes. Payers increasingly embrace value-based models that reward prevention and early intervention. All these factors align to create unusual receptivity for transformative respiratory technologies.
Returning to Hutchinson's Vision
The most compelling argument for continuous respiratory monitoring is neither commercial nor technological; it's clinical. We have failed 545 million patients by allowing a diagnostic paradigm designed for Victorian England to persist essentially unchanged into the 21st century [2]. The consequences of this failure are measured in preventable deaths, unnecessary hospitalisations, and decades of diminished quality of life.
Hutchinson understood something fundamental: lung function predicts mortality better than most measurements we routinely make. He was right in 1846, and the intervening research has only strengthened his insight. Reduced lung function in early adulthood predicts cardiovascular and all-cause mortality, as well as functional decline decades later. The lungs tell us who is at risk if we listen continuously rather than only occasionally.
Early detection before symptoms emerge was Hutchinson's original ambition. We now possess the technological capability to fulfil that vision on a population scale. Continuous monitoring can identify the gradual decline in small airway function that precedes clinical COPD by years. It can detect the early restrictive changes of interstitial lung disease when therapeutic intervention might still modify the disease course. It can stratify cardiovascular risk through respiratory parameters, enabling preventive interventions in patients who would otherwise go unrecognised.
This is not hypothetical. Clinical investigations are already demonstrating these capabilities. The question is whether healthcare systems, pharmaceutical companies, technology platforms, and regulatory bodies will move with sufficient urgency to translate proof-of-concept into widespread clinical implementation.
The Revolution Is Already Underway
The transformation of respiratory diagnostics from episodic to continuous, from clinic-based to patient-centric, from reactive to predictive is not a future possibility; it is happening now. Multiple platforms are in active clinical validation. Regulatory submissions are progressing. Pharmaceutical partnerships are forming. Healthcare systems are piloting implementation programmes.
The organisations that will lead this transformation share specific characteristics: deep clinical expertise in respiratory physiology, rigorous commitment to evidence-based validation, technical sophistication in signal processing and machine learning, and strategic vision that extends beyond incremental product improvements to genuine paradigm shifts in care delivery.
For pharmaceutical companies, the imperative is to rethink clinical development programmes around continuous monitoring from early-phase studies through post-marketing surveillance. For technology companies, the opportunity is to establish the data infrastructure and platform that becomes the global standard for respiratory health. For healthcare systems and payers, the challenge is to create reimbursement and care delivery models that incentivise prevention through continuous monitoring rather than reactive treatment of advanced disease.
The question is no longer whether continuous respiratory monitoring will transform medicine; the clinical evidence and technological capability are beyond debate. The question is who will drive that transformation, how quickly it will occur, and whether we'll move with sufficient urgency to impact the 545 million people currently suffering.
In 1846, John Hutchinson measured 2,130 subjects with a counterbalanced bell inverted in water and established that reduced lung function predicts mortality. One hundred and seventy-five years later, we finally have the means to fulfil his vision: detecting lung disease before symptoms appear, tracking disease progression continuously, and intervening early enough to alter trajectories. The technology exists. The clinical need is urgent. The commercial opportunity is substantial.
The race has already begun. The only question that remains is who will lead it.
Dr Bipin Patel CEO electronRx
This article reflects perspectives developed through an extensive review of the historical and contemporary literature on spirometry, respiratory diagnostics, and digital health innovation. For partnership enquiries regarding next-generation respiratory monitoring platforms, please contact electronRx.
